The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence
- PMID: 30384959
- DOI: 10.1016/j.ygyno.2018.10.013
The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence
Comment on
-
Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.Gynecol Oncol. 2018 Nov;151(2):190-195. doi: 10.1016/j.ygyno.2018.09.003. Epub 2018 Sep 27. Gynecol Oncol. 2018. PMID: 30268525
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
